{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:38:49Z","timestamp":1790303929084,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,2]]},"DOI":"10.7759\/cureus.76834","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T02:54:51Z","timestamp":1735872891000},"source":"Crossref","is-referenced-by-count":9,"title":["Triple M Overlap Syndrome: Myocarditis, Myositis and Myasthenia Gravis After a Single Administration of Pembrolizumab"],"prefix":"10.7759","author":[{"given":"Carlota","family":"Baptista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Margarido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Bizarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco P","family":"Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-38. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak R","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021, 26:1052-61. 10.1002\/onco.13931","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson JA","year":"2024","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al.. NCCN Guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024. J Natl Compr Canc Netw. 2024, 22:582-92. 10.6004\/jnccn.2024.0057","journal-title":"J Natl Compr Canc Netw"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer JR","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, et al.. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021, 9:2435. 10.1136\/jitc-2021-002435","journal-title":"J Immunother Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson DB","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, et al.. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019, 7:134. 10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093054","article-title":"Immune checkpoint inhibitor-related myositis: From biology to bedside","volume":"21","author":"Solimando AG","year":"2020","unstructured":"Solimando AG, Crudele L, Leone P, et al.. Immune checkpoint inhibitor-related myositis: From biology to bedside. Int J Mol Sci. 2020, 21:3054. 10.3390\/ijms21093054","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/874680","article-title":"Myasthenia gravis: a review","volume":"2012","author":"Jayam Trouth A","year":"2012","unstructured":"Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis. 2012, 2012:874680. 10.1155\/2012\/874680","journal-title":"Autoimmune Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem JE","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al.. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018, 19:1579-89. 10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood SS","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al.. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018, 71:1755-64. 10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13071243","article-title":"Immune checkpoint inhibitors-related myocarditis: a review of reported clinical cases","volume":"13","author":"Zotova L","year":"2023","unstructured":"Zotova L. Immune checkpoint inhibitors-related myocarditis: a review of reported clinical cases. Diagnostics (Basel). 2023, 13:1243. 10.3390\/diagnostics13071243","journal-title":"Diagnostics (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10264-0","article-title":"Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review","volume":"268","author":"Lotan I","year":"2021","unstructured":"Lotan I, Hellmann MA, Wilf-Yarkoni A, Steiner I. Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review. J Neurol. 2021, 268:4573-86. 10.1007\/s00415-020-10264-0","journal-title":"J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5812\/ijcm.114589","article-title":"What do emergency physicians know about immune checkpoint inhibitor-related toxicities: a brief report","volume":"14","author":"Butters T","year":"2021","unstructured":"Butters T, Liu WK, Grant M, et al.. What do emergency physicians know about immune checkpoint inhibitor-related toxicities: a brief report. Int J Cancer Manag. 2021, 14:114589. 10.5812\/ijcm.114589","journal-title":"Int J Cancer Manag"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/325330-triple-m-overlap-syndrome-myocarditis-myositis-and-myasthenia-gravis-after-a-single-administration-of-pembrolizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T02:54:52Z","timestamp":1735872892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/325330-triple-m-overlap-syndrome-myocarditis-myositis-and-myasthenia-gravis-after-a-single-administration-of-pembrolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.76834","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,2]]}}}